Celon Pharma SA
8RP
Company Profile
Business description
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
Contact
Ogrodowa 2A
Kielpin
Lomianki05-092
POLT: +48 227515933
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
566
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,032.00 | 53.10 | -0.58% |
| CAC 40 | 8,112.08 | 8.50 | 0.10% |
| DAX 40 | 24,315.71 | 24.35 | -0.10% |
| Dow JONES (US) | 48,710.97 | 20.19 | -0.04% |
| FTSE 100 | 9,876.16 | 5.48 | 0.06% |
| HKSE | 25,635.23 | 183.70 | -0.71% |
| NASDAQ | 23,593.10 | 20.21 | -0.09% |
| Nikkei 225 | 50,526.92 | 223.47 | -0.44% |
| NZX 50 Index | 13,525.99 | 3.07 | -0.02% |
| S&P 500 | 6,929.94 | 2.11 | -0.03% |
| S&P/ASX 200 | 8,725.70 | 51.00 | -0.58% |
| SSE Composite Index | 3,965.28 | 1.60 | 0.04% |